1.99
price down icon17.43%   -0.42
 
loading

Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten

pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan

May 23, 2025
pulisher
May 23, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World

May 23, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Breakthrough AL Amyloidosis Treatment Achieves 71% Complete Response Rate in First US Trial at ASCO - Stock Titan

May 22, 2025
pulisher
May 22, 2025

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune

May 22, 2025
pulisher
May 21, 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire

May 21, 2025
pulisher
May 19, 2025

We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Immix Biopharma — Steady progress in Q125 - Smartkarma

May 19, 2025
pulisher
May 05, 2025

Immix Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 01, 2025

Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st

Apr 30, 2025
pulisher
Apr 23, 2025

Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan

Apr 23, 2025
pulisher
Apr 03, 2025

Immix Biopharma — All eyes on NEXICART-2 - Smartkarma

Apr 03, 2025
pulisher
Mar 28, 2025

Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 25, 2025

Immix Biopharma Inc. (IMMX) reports earnings - Quartz

Mar 25, 2025
pulisher
Mar 20, 2025

Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 13, 2025

Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma

Mar 13, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Mar 12, 2025
pulisher
Mar 04, 2025

Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World

Mar 04, 2025
pulisher
Feb 13, 2025

HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis - OncLive

Feb 13, 2025
pulisher
Feb 12, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Feb 11, 2025
pulisher
Feb 10, 2025

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™

Feb 10, 2025
pulisher
Feb 10, 2025

Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks

Feb 10, 2025
pulisher
Feb 10, 2025

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail

Feb 10, 2025
pulisher
Feb 10, 2025

Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan

Feb 10, 2025
pulisher
Feb 06, 2025

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - The Globe and Mail

Feb 06, 2025
pulisher
Feb 06, 2025

Immix Biopharma : Presentation (IMMX Corporate presentation February 2025) - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

Is Qualcomm Stock a Buy Even Without Huawei Deal? - The Globe and Mail

Feb 06, 2025
pulisher
Feb 05, 2025

Several Insiders Invested In Immix Biopharma Flagging Positive News - Yahoo Finance

Feb 05, 2025
pulisher
Jan 20, 2025

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat

Jan 20, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Jan 14, 2025
pulisher
Jan 10, 2025

FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

HC Wainwright Predicts Weaker Earnings for Immix Biopharma - MarketBeat

Jan 09, 2025
pulisher
Jan 09, 2025

Immix Biopharma Inc (IMMX-Q) QuotePress Release - The Globe and Mail

Jan 09, 2025
pulisher
Jan 08, 2025

Immix Biopharma, Inc. Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - Marketscreener.com

Jan 08, 2025
pulisher
Jan 08, 2025

HC Wainwright Reaffirms “Buy” Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - The Manila Times

Jan 07, 2025
pulisher
Jan 07, 2025

Immix Biopharma Completes Critical Phase 1b Safety Trial for Novel AL Amyloidosis CAR-T Therapy - StockTitan

Jan 07, 2025
pulisher
Jan 06, 2025

Analyst maintains Buy on Immix Biopharma on initial results of NEXICART-2 trial - Investing.com India

Jan 06, 2025
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
Kapitalisierung:     |  Volumen (24h):